Skip to main content
BIIB
NASDAQ Life Sciences

Biogen to Advance Alzheimer's Drug Diranersen to Late-Stage Despite Phase 2 Miss

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$223.99
Mkt Cap
$30.196B
52W Low
$119.18
52W High
$205.97
52W Position info
88% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BIIB sits 88% above its 52-week low of $119.18.

Summary

Biogen announced its decision to advance the experimental Alzheimer's drug, Diranersen, into late-stage trials, despite the treatment failing to meet its primary endpoint in a mid-stage (Phase 2 Celia) study. The drug did not show that higher doses were more effective than lower ones in tracking dementia severity. This strategic decision to continue development, despite the mixed results, is a significant update for the company's pipeline, especially given the high unmet need in Alzheimer's. The market reacted positively, with shares up over 6% in premarket trading, indicating that investors view the continuation of the program as a net positive, outweighing the mid-stage trial miss. Traders will now watch for further details on the late-stage trial design and future data readouts.

At the time of this announcement, BIIB was trading at $223.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $119.18 to $205.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $249.28 info
Change: $0 (0%) info
Market Cap: $36.894B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $249.28 info
Change: -$3.72 (-1%) info
Market Cap: $36.894B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $249.28 info
Change: +$0.930 (+0.37%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $249.28 info
Change: -$3.45 (-1%) info
Market Cap: $36.894B info